Join us at the ATS conference to learn how we enable the early prediction of clinically-significant deterioration of critically ill patients. May 19-24, 2017.

On May 19-24, 2017, Dr. Itai Pessach, Medical Director of CLEW (previously known as Intensix), will be at the American Thoracic Society’s Conference in Washington DC to present the company’s latest results in the development of prediction models for early detection of significant deterioration events.

The study focuses on Inensix’s use of machine learning algorithms combined with processing and analysis of large quantities of data automatically acquired in real-time from the electronic medical record (EMR). This tool alerts the physician that life-threatening events – such as sepsis, shock and respiratory failure – are in progress, leading to the rapid initiation of appropriate care. Interventions at this level reduce morbidity, mortality and length of stay in the Intensive Care Unit (ICU).

Dr. Pessach is an assistant Professor of pediatrics at the Tel-Aviv University and a senior pediatric critical care physician at Sheba Medical Center. He is certified in allergy immunology and in pediatric critical care. He has a broad background in basic and clinical research and has published extensively in the fields of pediatric immunology and critical care. Dr. Pessach holds an MD, PhD degree from the Ben-Gurion University and has trained both at Sheba medical center as well as at Children’s Hospital Boston, Harvard Medical School.